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Introduction
Cardiovascular (CV) drug development urgently needs 
enhanced screening systems that enable improved early stage 
assessments of drug hazard and more accurately predict in 
vivo drug toxicity and clinical efficacy.1,2 Multicellular syncy-
tia of human stem cell–derived cardiomyocytes (hSCCMs, 
which encompass both embryonic stem cell–derived CMs 
[ESCMs] and induced pluripotent stem cell–derived CMs 
[iPSC-CMs]) have emerged as important new tools for drug 
screening.1,3–5 These models re-create, to some extent, the cell-
to-cell communication that modulates cellular behavior in vivo 
and obviate some of the issues associated with nonhuman cell-
based assays. However, there are acknowledged issues regard-
ing their hybrid embryonic-adult proteomic and transcriptomic 
signatures, cellular heterogeneity postdifferentiation, intracel-
lular microarchitecture and signaling organization, electro-
physiological profiles, and pharmacological sensitivities.
The incorporation of hSCCM-based assays into the drug 
discovery toolkit now warrants the development of improved 
systems that can better interrogate the rich information that 
these new cellular models have the potential to yield. 
Moreover, the shift toward phenotypic profiling strategies, 
which evaluate drug bioactivities in the context of a deep 
understanding of cellular signaling networks, requires 
methodological innovation beyond the transposition of con-
ventional optical and electrophysiological technologies 
onto these new cell systems.1,2
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Abstract
The emergence of human stem cell–derived cardiomyocyte (hSCCM)–based assays in the cardiovascular (CV) drug discovery 
sphere requires the development of improved systems for interrogating the rich information that these cell models have 
the potential to yield. We developed a new analytical framework termed SALVO (synchronization, amplitude, length, 
and variability of oscillation) to profile the amplitude and temporal patterning of intra- and intercellular calcium signals in 
hSCCM. SALVO quantified drug-induced perturbations in the calcium signaling “fingerprint” in spontaneously contractile 
hSCCM. Multiparametric SALVO outputs were integrated into a single index of in vitro cytotoxicity that confirmed the 
rank order of perturbation as astemizole > thioridazine > cisapride > flecainide > valdecoxib > sotalol > nadolol ≈ control. 
This rank order of drug-induced Ca2+ signal disruption is in close agreement with the known arrhythmogenic liabilities of 
these compounds in humans. Validation of the system using a second set of compounds and hierarchical cluster analysis 
demonstrated the utility of SALVO to discriminate drugs based on their mechanisms of action. We discuss the utility of this 
new mechanistically agnostic system for the evaluation of in vitro drug cytotoxicity in hSCCM syncytia and the potential 
placement of SALVO in the early stage drug screening framework.
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The calcium (Ca2+) signaling network underpins virtually 
every biological phenomenon,6 and thus understanding the 
spatiotemporal organization of Ca2+ signals in functionally 
coupled hSCCMs, under normal and drug-exposed conditions, 
could potentially reveal the mechanistic bases of drug-evoked 
phenotypic modulation and cellular (dys)function.7–9 Previous 
studies in single mammalian cells showed that subtle changes 
in Ca2+ signaling dynamics, which did not perturb steady-state 
Ca2+ homeostasis, had profound consequences for cell pheno-
type.6,10–12 In this study, we extend these approaches to profile 
Ca2+ signal organization in spontaneously contractile, func-
tionally coupled hSCCMs. We describe the development and 
proof-of-concept validation of a novel system (termed SALVO: 
synchronization, amplitude, length, and variability of oscilla-
tions) that enables a detailed interrogation of the spatiotempo-
ral patterning of Ca2+ signals in hSCCMs and the exploration 
of the mechanisms of drug action. We discuss the potential 
utility of this system in the drug safety screening landscape and 
how, in combination with other contemporary screening 
approaches, SALVO may enable a better understanding of the 
mechanisms underlying CV drug cytotoxicity and lead to the 
improved prediction of drug hazard in humans.
Materials and Methods
Cytiva Culture and Maintenance
Cytiva hSCCMs were derived from monolayer differentia-
tion of an H7 hESC cell line that had been expanded under 
feeder-free conditions and then subjected to a proprietary dif-
ferentiation protocol (GE Healthcare, Piscataway, NJ, USA).13 
Cytiva were supplied as a heterogeneous cell population con-
taining 50.5% ± 5.4% cardiomyocytes (n = 6 batches; batch 
numbers 4799455, 4903456, 4638600, 4636900, 7396634, 
6265575). Cells were thawed and seeded into 7-mm2 cham-
bers created by the adherence of silicon gaskets (CultureWell 
MultiWell 3 mm in diameter, 1-mm-depth inserts [Life 
Technologies]) on glass-bottomed culture chambers (In Vitro 
Scientific, Sunnyvale, CA, USA) that had been precoated 
with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), 
Franklin Lakes, NJ, USA diluted 1:30 (v/v) in Knockout 
DMEM (Life Technologies, Carlsbad, CA, USA). Cells were 
seeded as per the manufacturer’s instructions at a density of 
2500 cells per mm2 surface area (i.e., 17,500 cells in each 
7-mm2 chamber corrected for plating efficiency) in antibi-
otic-free RPMI 1640 (15 µL) supplemented with B27 (1:50 
[v/v] dilution) (RPMI/B27) (Life Technologies) and main-
tained at 37 °C in a humidified 5% CO2 environment. Cells 
were allowed to adhere to the coverslip for 2 h before the dish 
was filled with RPMI/B27 (2 mL). Medium was exchanged 
every 48 h.
Immunofluorescent Detection of Troponin-T
Cells were fixed (4% [v/v] formaldehyde in phosphate-
buffered saline [PBS], containing [in mM] NaCl [140], KCl 
[2.7], Na2HPO4 [10], NaH2PO4 [2], pH 7.4) for 10 min at 
room temperature (RT) and then washed three times with 
PBS prior to permeabilization (0.1% [v/v] Triton X-100 in 
PBS, 4 min at RT). Nonspecific antibody interactions were 
blocked by incubation in horse serum (4% [v/v] in PBS, 1 h, 
RT) before cells were incubated with mouse anti–troponin-
T (TnT; 1:200 [v/v] in PBS) (MA5-12960; Thermo 
Scientific, Waltham, MA, USA) overnight at 4 °C. Cells 
were washed with PBS (3 × 5 min) before being incubated 
with Alexa Fluor 546 anti–mouse IgG (1:200 [v/v]; Life 
Technologies) for 1 h at RT in the dark. Following washing 
with PBS (3 × 5 min), cell nuclei were counterstained with 
DAPI (1 µg/mL; 20 min) prior to further washing in PBS 
(2 × 1 min) and mounting under Prolong Gold (Life 
Technologies). Cells were imaged using a confocal microscope 
(SP5; Leica Microsystems, Wetzlar, Germany), and assess-
ments of TnT positivity and cellular alignment were made 
using image analysis (LAS-AF [Leica Microsystems] and 
ImageJ [National Institutes of Health, Bethesda, MD, USA]).
Ca2+ Imaging and Analysis of Ca2+ Signals
Cells were incubated with fluo-4 AM (5 µM) (Life 
Technologies) for 1 h at 37°C before coverslips were flooded 
with RPMI/B27 (2 mL). Fluo-4 Ca2+-dependent signals were 
visualized in 0.021-mm2 regions with a 63× oil immersion 
objective (NA 1.4) using argon laser excitation (488 nm) and 
a confocal microscope (SP5; Leica Microsystems). Cells 
were maintained at 37 °C throughout experiments. Images 
were recorded every 100 ms at a 512 × 512–pixel resolution. 
The application of caffeine (5 mM final concentration) was 
used to trigger sarcoplasmic reticulum (SR) Ca2+ release and 
thereby estimate the intra-SR Ca2+ store load.
Taking our lead from Uhlen’s method of using spectral 
analysis to investigate the organization of Ca2+ signals,14 we 
developed SALVO to decode the spatiotemporal patterning 
of Ca2+ oscillations within individual cells and across mul-
ticellular populations. SALVO outputs 30 parameters that 
describe Ca2+ signal organization,15 but for the purposes of 
this study, we focused on five parameters: oscillation rate 
(rate, Hz) and four other parameters that quantify the ampli-
tude and temporal patterning of Ca2+ oscillation: (1) ampli-
tude heterogeneity index (AHI) and (2) temporal 
heterogeneity index (THI), statistical assessments of signal 
amplitude and temporal variability within single cells, 
respectively; (3) intertransient noise (ITN), defined as the 
Ca2+ signal variability occurring between Ca2+ oscillations 
and that extends the use of signal variability (SV) to mea-
sure point-by-point differences in very low-amplitude Ca2+ 
signals6,10,12; and (4) synchronization, an index of the tem-
poral coincidence of Ca2+ oscillation maxima occurring 
across cells in the population. The calculation of these 
parameters is described in Supplementary Figure S1. 
SALVO is implemented using a Python-based computer 
program.15 The detection of signal maxima and minima 
over a 30-s period in data obtained from 6 to 20 cells in each 
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instance was performed using SALVO’s autodetection 
algorithms (based on spline detect or threshold detection 
methods) or by manual assignation of the start, peak, and 
end of each Ca2+ spike. SALVO outputs were archived and 
interrogated using a custom-built SQL-based database sys-
tem (DB Miner, CHG, NCS, SBJ).
Characterization of Drug-Evoked Ca2+ 
Perturbation
Baseline assessments of Ca2+ signals in fluo-4–loaded cells 
prior to the addition of drug (control) were established as 
described above. Cells were then sequentially exposed to 
increasing concentrations of cardioactive drugs, selected to 
represent those categories assigned by Redfern and col-
leagues16 as category 1 (“repolarization-prolonging as an 
intended, desirable effect”; sotalol, prescribed as a β-blocker 
with class III antiarrhythmic properties17), category 2 
(“drugs that have been withdrawn or suspended from the 
market in at least one major regulatory territory due to an 
unacceptable risk of TdP”; astemizole and cisapride, 
QT-prolonging IKr/hERG-blocking antihistamine and gas-
tric prokinetic, respectively), category 3 (“drugs that have a 
measurable incidence of TdP in humans”; thioridazine, a 
drug with the highest incidence of TdP among prescribed 
antipsychotics via off-target effects on IKr/hERG,
18 and fle-
cainide, a torsadogenic class IC antiarrhythmic [Nav1.5 
channel blocker]17), and category 5 (“no published reports 
of TdP in humans”; nadolol, a nonselective β-blocker). 
Valdecoxib, a COX-2–selective nonsteroidal anti-inflam-
matory drug (NSAID) that was initially approved for use in 
the treatment of osteoarthritis and rheumatoid arthritis but 
was subsequently withdrawn from the market due to adverse 
CV effects,19 was not included in the assessment by Redfern 
et al.16 but was included here. We purchased rofecoxib 
(Vioxx) from Sequoia Research Products (Pangborne, UK), 
but the supplied compound exhibited inconsistent bioactiv-
ity in our assay system.
Stock solutions of drugs (10 mM) in ultrapure water or 
tissue-culture grade DMSO were diluted in RPMI/B27, and 
the concentration of each drug under test was sequentially 
increased. After each addition and following a period of 
equilibration (approximately 90 s), fluo-4–dependent Ca2+ 
signals were acquired for 30 s. Using this protocol, the same 
population of cells was imaged throughout the entire drug 
addition sequence.
To validate the system, we used a second set of com-
pounds at maximal effective concentrations in our assay (1–
30 µM): category 1, amiodarone (class III antiarrhythmic); 
category 2, terodiline (QT-prolonging proarrhythmic); cate-
gory 5, metoprolol (selective β1-blocker); celecoxib (COX-2 
inhibitor), and aconitine (non–QT-prolonging proarrhyth-
mic). We also included two drugs that have mechanisms of 
actions distinct from those above: verapamil (L-type Ca2+ 
channel blocker, category 5) and ranolazine (late INa current 
inhibitor). In all experiments, operators were blinded to the 
identities of the drugs under test throughout all phases of 
postexperimental data analysis.
Electrophysiological Recordings of Action 
Potentials in Cytiva
Cells in 35-mm glass-bottomed culture dishes containing a 
superfusion insert (AutoMate PCP-1; Digitimer Ltd., Welwyn 
Garden City, UK) were mounted on the stage of an inverted 
microscope (CKX-41; Olympus, Tokyo, Japan) and were 
superfused with normal Tyrode (NT) solution (containing [in 
mM] NaCl [145], KCl [4], MgCl2 [1], CaCl2 [2], HEPES 
[10], glucose [10]; pH 7.4 with NaOH) or NT-containing 
drugs maintained at 37 °C using a heated jacket.
Cells were whole-cell clamped with 3- to 4-MΩ patches 
and an intrapipette solution (containing in [mM] KCl [120], 
MgCl2 [1.75], CaCl2 [5.37], EGTA [10], HEPES [10], and 
Na2ATP [4]; pH 7.2 with KOH) in current-clamp (IC) mode 
using a CV-7B headstage and MultiClamp 700B amplifier 
controlled by MultiClamp software (Molecular Devices, 
Sunnyvale, CA). Data were digitized and acquired using a 
Digidata 1322a card and pClamp software, respectively 
(Molecular Devices). Action potentials were sampled at a 
rate of 20 kHz and low pass (Bessel) filtered at 10 kHz.
Spontaneous cell contracture was terminated using bleb-
bistatin (5 µM, 10 min), an agent that inhibits myofilament 
shortening and thereby negates patch-clamp recording 
instability but preserves normal Ca2+ cycling.20 Following 
cessation of contractures, spontaneous action potentials 
were observed in all cells following the application of a cur-
rent pulse to obtain whole-cell access. Action potential (AP) 
recordings from blebbistatin-immobilized cells were taken 
under control (no-drug) conditions (1 min) and following 
the switch to drug-containing NT. APD90, corrected for AP 
cycle length using Fridericia’s method (APD90(corr) = APD90/
cycle length0.3), was calculated from five consecutive APs 
following a 3-min exposure of the cells to drug.
Hierarchical Clustering and Statistical Analysis
Hierarchical clustering of SALVO outputs was performed 
using the uncentered correlation similarity metric and cen-
troid clustering method in Cluster 3.0 (Lawrence Berkley 
Laboratories, CA, USA) with output visualization using 
TreeView (v1.1.6r4; JAM Software, Trier, Germany). Data 
sets were tested for normality using the D’Agostino-Pearson 
algorithm, and normally distributed data were compared 
using analysis of variance with intergroup comparisons per-
formed using Bonferroni’s post hoc test. Nonnormally dis-
tributed data were compared using the Kruskal-Wallis test 
with Dunn’s post hoc test. For comparing only two groups 
of data, two-tailed Student t test (normal) or the 
 at Cardiff University on December 2, 2014jbx.sagepub.comDownloaded from 
4 Journal of Biomolecular Screening 
Mann-Whitney test (nonnormal) was used. All statistical 
analysis was performed using Prism 6.0 (GraphPad 
Software, La Jolla, CA, USA). All data are given as mean ± 
standard error (SE). A p value of 0.05 was considered statis-
tically significant.
Results and Discussion
Profiling the Functional Maturation of Ca2+ 
Handling
The relative axial alignment of TnT-positive cardiomyocytes 
(CMs) was low on days 2 and 3 postseeding but progressively 
increased to a maximum at day 5 with no further change to day 
7 (Fig. 1A–C). This alignment of cells was associated with the 
intracellular redistribution of TnT that transitioned from a form 
that lacked apparent organization (day 2) into well-defined 
striatal arrangements (days 4–7) (Fig. 1A,C). The proportion 
of TnT-positive CMs remained constant between days 2 and 7, 
suggesting a stable population of differentiated CMs and the 
absence of proliferative or differentiation-competent contami-
nant non-CM cells (Fig. 1B). Cells between days 2 and 7 
exhibited robust responses to caffeine, and contrary to a report 
that only a subset of hSCCMs is caffeine sensitive (approxi-
mately 38%),21 all Cytiva CMs possessed the requisite cellular 
machinery to support caffeine-induced Ca2+ release even by 
day 2 postseeding (Suppl. Fig. S2). However, the amplitude of 
caffeine-induced Ca2+ release, an index of the functional Ca2+ 
storage capacity of the SR, was augmented at day 4 and 
remained unchanged through day 7 (Fig. 1D and Suppl. Fig. 
S2). CMs between days 4 and 7 also exhibited a faster rate of 
Ca2+ sequestration/extrusion after caffeine-induced Ca2+ 
release (Suppl. Fig. S2).
Our data point to the culture-dependent alignment of 
CMs, the intracellular reorganization of TnT, and the 
improved functional capacity of the Ca2+ handling machin-
ery and corroborate reports of progressive SR maturation in 
cultured hSCCMs.21 Although our study did not establish 
the causal drivers of these phenomena, we observed that 
day 4 CMs exhibited maximal amplitude and kinetics of 
caffeine-induced Ca2+ release (Fig. 1D and Suppl. Fig. S2), 
yet were incompletely aligned (Fig. 1C). This suggests a 
complex association between changes in cellular morphol-
ogy, subcellular architecture, and functional modulation of 
the SR Ca2+ store that requires further investigation. The 
progressive alignment of cells from day 3 was not associ-
ated with increased levels of cell death in the population 
that remained consistently low (cell death [%]: day 3, 2.0 ± 
0.8; day 4, 1.1 ± 0.4; day 5, 1.5 ± 0.4; day 6, 1.4 ± 0.6; day 
7, 1.9 ± 0.5; p = 0.8573).
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Figure 1. Phenotypic 
characterization of Cytiva. (A) 
The subcellular distribution 
of troponin-T (TnT; red) was 
visualized. Cell nuclei were stained 
with DAPI (blue). Arrow indicates 
TnT striation. Scale bar = 20 µm. 
(B) The proportion of TnT-positive 
cardiomyocytes (n = 28–40 separate 
image fields). (C) The relative 
alignment of cells. The maximum 
value (100%) represents every cell 
aligning along a single axis. Data are 
mean ± SE (n = 23–48 image fields). 
*p < 0.05. ***p < 0.001. (D) The 
amplitude of Ca2+ release triggered 
by caffeine (5 mM). Data are mean ± 
SE (n > 4 fields of view, n > 12 cells 
in each instance). *p < 0.05.
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The morphological and Ca2+ signaling changes observed 
at day 4 coincided with the onset of spontaneous Ca2+ oscil-
lations (53.6% ± 19.7% cells on day 4 exhibited spontane-
ous Ca2+ oscillations vs. 0% on day 3, p < 0.0001) and 
synchronized contraction (Fig. 2A(i) and Suppl. Movies 
1–3). Between days 4 and 7, the proportion of cells exhibit-
ing spontaneous Ca2+ release remained static (day 5, 65.0% 
± 18.9%; day 6, 64.8% ± 14.3%; day 7, 59.2% ± 13.1%; p = 
0.505), but the Ca2+ oscillations became qualitatively 
(Fig. 2A(ii)) and quantitatively (Fig. 2B) better organized 
(see also Suppl. Fig. S3). Notably, there was a marked 
decrease in AHI and THI (indices that tend to zero with 
reduced amplitude and temporal variability of spontaneous 
Ca2+ release) and a reduction in ITN, indicative of less vari-
ability in low-amplitude Ca2+ signals occurring between 
large Ca2+ transients (Fig. 2B). Taken together, the attenua-
tion of AHI, THI, and ITN suggests an improvement in the 
amplitude and temporal organization of Ca2+ oscillations 
between days 4 and 7. These data extend our findings that 
pivotal changes in cell morphology, alignment, and Ca2+ 
signaling that occur between days 3 and 4 drive the onset of 
spontaneous Ca2+ oscillations, which become progressively 
better organized to day 7. Intercellular synchronization of 
Ca2+ oscillations remained unchanged between days 4 and 7 
(Fig. 2B), indicating that functional cell-to-cell coupling 
established by day 4 was unaffected by subsequent pheno-
typic changes. Cell density, which varied between 200 and 
1000 cells/mm2 depending on batch number and the plating 
efficiency of the cells, had no measureable effect on the 
Ca2+ handling behavior of the cells or on the extent of inter-
cellular synchronization (Suppl. Fig. S4). It has been 
reported that hSCCMs plated at “low density” (500–1200 
cells/mm2) exhibit markers of cellular hypertrophy and 
electrical remodeling.22 Although our mean cell densities 
were below this threshold, the alignment of cells in culture 
leads to regional heterogeneity, with some regions at very 
high densities and other areas that contain few cells (see 
Fig. 1). Since there was no increase in cell death to day 7, 
the contribution of cell death to the observed distribution of 
cells can be excluded. We did not investigate the functional 
impact of more uniformly distributed regions of high cell 
densities (>1200 cells/mm2) on Cytiva CM phenotype.
The optimal functional state of Cytiva CMs (i.e., like 
that determined on days 6 and 7; Suppl. Fig. S3) existed 
only for a short period. Beyond day 7, the proportion of 
TnT-positive cells progressively decreased, and by day 14, 
there was a pronounced functional deterioration in Ca2+ sig-
naling (Suppl. Fig. S5). At day 21, the few cells that 
remained adherent (typically 5%–10% of those present at 
day 7) had mostly reverted to fibroblastic-like morpholo-
gies with a loss of TnT striation and organization (Suppl. 
Fig. S5). This short window meant that we performed all 
subsequent experiments on CMs between days 6 and 8. We 
did not pursue strategies reported to prolong hSCCM func-
tionality (e.g., optimized replating cycles23), and it is likely 
that such protocols could improve the functional longevity 
of Cytiva in culture.
Using Ca2+ Signal Perturbation to Assess Drug-
Induced Cytotoxicity
The disruption of the spatiotemporal patterning of Ca2+ sig-
nals is a hallmark of cellular dysfunction, and so we next 
investigated the propensity of cardioactive drugs to perturb 
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Figure 2. Functional maturation 
of Ca2+ cycling in Cytiva. (A) (i) 
Ca2+ traces from six representative 
cells. (ii) Expanded sections 
depicted by dashed lines in (i). 
Data for days 2 through 7 are given 
in Supplementary Figure S3. 
(B) A five-parameter description 
of Ca2+ signal organization in 
spontaneously oscillating cells. Data 
are from ≥5 separate experiments. 
**p < 0.01. ****p < 0.001. Data 
from days 4 through 7 are given in 
Supplementary Figure S3.
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intra- and intercellular Ca2+ signal organization. Nadolol, a 
nonselective β-blocker with an excellent clinical safety pro-
file, had no measurable effect on Ca2+ handling at concen-
trations up to 30 µM (Fig. 3 and Suppl. Table S2). Sotalol, 
a class III antiarrhythmic that has been reported to have 
QT-prolonging effects at therapeutic plasma concentrations 
exceeding 10 µM, caused an isolated change in AHI at con-
centrations >1 µM but did not reduce the extent of intercel-
lular synchronization (Fig. 3 and Suppl. Table S2). 
Concentration-response profiling revealed that drugs with 
recognized proarrhythmic hazards resulting from hERG-
blocking activities (astemizole, cisapride, thioridazine) or 
via other “non-hERG” mechanisms (flecainide, valde-
coxib) evoked large effect sizes in multiple parameters of 
Ca2+ handling (Fig. 3 and Suppl. Table S2). These data 
confirmed that the perturbation of cellular Ca2+ signals in 
vitro is a hallmark feature of drugs with known cardiovas-
cular risk in humans irrespective of whether their proar-
rhythmic mechanism of action involves IKr/hERG 
blockade. Notably, SALVO quantified the Ca2+-disrupting 
effects of valdecoxib, a drug that had hitherto not been 
considered to exert direct effects on CMs using conven-
tional electrophysiological assessments. Our data are con-
sistent with those of Pyrko and colleagues,24 who reported 
the elevation of cytoplasmic Ca2+ within seconds of the 
addition of 2,5-dimethyl-celecoxib, an analogue valde-
coxib, to glioblastoma cells. These findings add weight to 
the concern that contemporary electrophysiological mea-
surements do not adequately resolve potential CV risk 
associated with some drugs, especially those that do not 
directly modulate cellular Na+ and K+ ion handling. 
Illustrating this point, impedance measurements in 
hSCCM failed to identify the potential hazard associated 
with rofecoxib (Vioxx),25 an analogue of valdecoxib that 
was withdrawn because of unacceptable CV risk.19 We 
believe that SALVO has the potential to occupy this void 
in the contemporary drug screening landscape.
To further corroborate the utility of SALVO to identify 
potential CV drug hazard that arises from diverse mechanis-
tic bases, we profiled the effects of these same drugs on 
spontaneous APs. Cytiva CMs were characterized by rest-
ing membrane potentials of approximately −60 mV and 
exhibited ventricular-like waveforms (Fig. 4). Astemizole, 
cisapride, and thioridazine increased APD90, entirely in 
keeping with their known IKr/hERG blocking activities. 
However, flecainide and valdecoxib, drugs that markedly 
perturbed Ca2+ signals (Fig. 3) and are known to increase 
proarrhythmic susceptibility in some circumstances,16,19 
had no effect on action potential duration (Fig. 4A,B). 
These data reinforce the use of SALVO to profile com-
pounds based on their disruption of cellular Ca2+ signal 
organization irrespective of whether the drugs in question 
modulate the electrophysiological profile of hSCCMs.
Cytiva are supplied as a heterogeneous mix of CMs and 
non-CMs. It is therefore plausible that effects of drugs on 
contaminant non-CMs could influence the measured effect 
on CMs (e.g., EC20 values). We used a fluorescence-acti-
vated cell sorting (FACS)–based strategy to enrich CMs, 
but the small population of viable yet morphologically 
abnormal CMs that were obtained offset any improvement 
in Ca2+ signal organization observed in post-FACS CMs 
(Suppl. Fig. S6).
Calculation of a SALVO Toxicity Score and Its 
Alignment with Proarrhythmic Risk in Humans
The five-parameter SALVO output (Fig. 3) was integrated 
into a single in vitro cytotoxicity score (SALVO toxicity 
score). The rank order of the extent of Ca2+ perturbation 
(astemizole > thioridazine > cisapride > flecainide > valde-
coxib > sotalol > nadolol) was in very close agreement with 
the known proarrhythmogenic liabilities of these drugs in 
humans13,16,25,26 (Fig. 5A and Suppl. Fig. S7). Moreover, 
SALVO exhibited a superior correlation with established 
CV drug risk in humans compared with electrophysiologi-
cal readouts (APD90, impedance measurements). Thus, for 
the reasons outlined above, we propose that SALVO will 
improve early stage assessments in CV drug hazard liabili-
ties. However, the extrapolation of in vitro cell-based toxic-
ity outputs to risk prediction in clinical scenarios is 
problematic,1,2 and it is accepted that, at present, no single 
approach can accurately translate in vitro readouts to drug 
effects in humans. Consequently, SALVO outputs should be 
appropriately integrated with information obtained from 
other platforms (e.g., electrophysiology).
There is also the issue regarding the relevance of drug 
potency determined in vitro to clinical dosing in humans. 
Guo and colleagues25,27 used an impedance-derived index 
of arrhythmic beating in hSCCMs to derive a predicted pro-
arrhythmic score (PPS) that took into account the therapeu-
tically relevant total concentration of drug in human plasma 
(defined as Ceff). More recently, Clements and Thomas
13 
used a similar approach to generate a predictive risk score 
(PRS) based on their measurement of field potential dura-
tion (FPD) in Cytiva. In keeping with these studies, we 
adjusted the five-parameter SALVO output to account for 
the free plasma concentration of the clinically effective 
drug (ETPCunbound) (Suppl. Tables S1 and S2). Our resul-
tant PPS (ETPCunbound/EC20) (Suppl. Fig. S8) described a 
rank order of thioridazine > cisapride > valdecoxib that was 
entirely consistent with the SALVO toxicity scores (Fig. 
5A) and aligned closely to the recognized hazards that these 
drugs pose in humans. However, flecainide exhibited an 
elevated PPS at odds with its relatively low proarrhythmia 
risk in humans. Moreover, anomalous PPS values for sotalol 
(PPS ~15) and astemizole (PPS <1) grossly misrepresent 
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the CV hazard associated with sotalol (low) and astemizole 
(high)16 (Suppl. Fig. S8). The erroneous values for these 
two drugs, which were also noted by Clements and 
Thomas,13 result from skew introduced by very high and 
low ETPCunbound values (14,733 and 0.2 nM for sotalol and 
astemizole, respectively) (Suppl. Table S1). Consequently, 
our data highlight the significant potential for the mislead-
ing categorization of “risk” following the calculation of a 
PPS or PRS (i.e., the adjustment of in vitro toxicity scores 
using clinically relevant plasma drug concentrations). These 
data strongly suggest that such simple indices are unlikely 
to accurately predict in vivo risk/hazard. However, by 
studying a larger set of compounds with known risk, 
together with consideration of other factors that influence in 
vivo drug responses, our future understanding of the rela-
tionship between in vitro assay outputs and CV risk in 
humans should be improved.
Hierarchical Clustering Analysis of SALVO 
Outputs to Discriminate Mechanisms of Drug 
Action
To further validate the system and to investigate the ability of 
SALVO to discriminate drugs based on their mechanisms of 
action, we tested a second set of compounds (see Materials 
and Methods). Hierarchical cluster analysis (HCA) revealed 
that, as anticipated, drugs with comparable mechanisms of 
action clustered together—for example, hERG blockers 
(terodiline with astemizole), non-hERG blockers (aconitine 
with flecainide), COX-2 inhibition (celecoxib with valde-
coxib), class III antiarrhythmics (sotalol with amiodarone), 
and β-blockers (nadolol with metoprolol) (Fig. 6). 
Importantly, we studied two cardioactive drugs selected on 
the basis of distinct mechanisms of action to those com-
pounds used above. Verapamil, a clinically safe L-type Ca2+ 
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Figure 3. Profiling cardiovascular drug-evoked perturbations in Ca2+ signals. Spontaneously oscillating cells were exposed to 
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channel blocker, reduced the rate of Ca2+ oscillation at very 
high concentrations of drug (>10 µM) but otherwise had no 
measurable effect on cellular Ca2+ handling. Ranolazine, an 
inhibitor of the late INa that is not associated with elevated CV 
hazard,28 reduced intercellular synchronization against a 
background of unchanged Ca2+ cycling. Consistent with their 
different mechanisms of action, verapamil and ranolazine 
were separated in the resultant dendrogram and did not clus-
ter with the other compounds tested in this study (Fig. 6). 
These data support the conclusion that SALVO discriminates 
compounds based on their mechanism of action. This analy-
sis used data obtained from the maximally effective concen-
tration of drug to reconcile the impact of these compounds on 
cellular Ca2+ signaling with their known mechanisms of 
action. However, these concentrations (typically >1 µM; see 
Fig. 6) greatly exceed the free plasma levels of drug achieved 
via clinical dosing regimes.16,29 We emphasize therefore that 
Figure 6 shows the clustering of drugs based on their mecha-
nisms of action and not on their established safety/risk profile 
in humans.
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Figure 4. Investigating the effect of 
cardiovascular-active drugs on Cytiva 
APD90. (A) Cells were exposed to 
drugs at EC20 concentrations for 
3 min (Suppl. Table S2). APD90 
values were corrected for beat period 
using Fridericia’s algorithm. Data 
points represent individual paired 
experiments (n = 6). Representative 
control (gray) and drug-treated (black) 
action potential traces are shown. 
(B) APD90 plotted as the percentage 
change relative to the paired control 
value (no drug). *p < 0.05. **p < 0.01.
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Future Directions
This study reports the development and proof-of-concept 
validation of SALVO, a new system to quantify drug-
induced (dys)organization of intra- and intercellular Ca2+ 
signaling in hSCCM populations. We propose that SALVO 
fills a current void in the early stage drug screening process, 
specifically via its ability to identify those compounds that 
exhibit CM cytotoxicity (and thus potentially increase pro-
arrhythmic susceptibility) but have negligible impact on the 
cellular electrophysiological profile. We also demonstrate 
the utility of SALVO to discriminate drugs based on their 
mechanism of action. The present work used only a small 
number of compounds of known proarrhythmia risk, and 
clearly, a systematic evaluation of a much larger panel of 
compounds is now warranted.
The comparative assay miniaturization reported here—
17,500 cells seeded in 7-mm2 gaskets and with the potential 
to use fewer cells still—suggests that this system is amenable 
to scaling to higher throughput formats (e.g., 384-well 
plates). Moreover, the system could be configured toward 
“multiplexing” ion-sensitive fluorescent probes or in combi-
nation with electrophysiological platforms.30 Outside of the 
predictive toxicology arena, such detailed assessments of cel-
lular Ca2+ signaling may also be useful in quality control (QC) 
processes, cellular phenotyping, and profiling batch-to-batch 
variability during the manufacture/differentiation process. It 
is also noteworthy that SALVO analysis could be applied to 
any oscillatory biological signal. To this end, it is of interest 
to explore SALVO in the context of other cell systems (e.g., 
hepatocytes) and to the analysis of other cellular signals that 
change on different timescales (e.g., pH).
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